Novel function of histamine signaling in hyperlipidemia‐induced atherosclerosis: Histamine H1 receptors protect and H2 receptors accelerate atherosclerosis

Histamine is not only essential for acute inflammatory reactions, but it also participates in a chronic inflammatory disorder. We generated apolipoprotein E (apoE) and histamine receptors (HHRs), including the major H1 and H2 receptors (HH1R, HH2R) double knockout mice (DKO) to clarify the role of HHRs in hyperlipidemia‐induced atherosclerosis, in which apoE‐KO and DKO mice were fed a high cholesterol diet. We found that pronounced hyperlipidemia‐induced atherosclerotic progression occurred in HH1R/apoE‐DKO mice, but in HH2R/apoE‐DKO mice less atherosclerosis, despite pro‐atherogenic serum cholesterol levels compared with apoE‐KO mice. Furthermore, the increased expressions of scavenger receptors (SRs), such as SR‐A, CD36 and lectin‐like oxidized low‐density lipoprotein receptor 1 (LOX‐1), nuclear factor‐kappa B (NFκB), monocyte chemoattractant protein (MCP‐1), matrix metalloproteinases (MMPs) or liver X receptor (LXR)‐related inflammatory signaling factors, were consistent with the pro‐atherogenic phenotype of HH2R/apoE‐DKO mice. We hypothesize that histamine/HH1R and HH2R signaling has conflicting innate functions, inflammatory/atherogenic and anti‐inflammatory/anti‐atherogenic actions, and that there are innate links between histamine signaling and hyperlipidemia‐induced atherosclerosis, independently of serum cholesterol metabolism. Specific histamine signaling blockers, in particular, HH2R blockers, are a possible novel therapeutic target for hyperlipidemia‐induced atherosclerosis.